INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 63 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2016. The put-call ratio across all filers is 0.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $52,000 | -33.3% | 97,413 | -3.0% | 0.00% | -50.0% |
| Q4 2017 | $78,000 | -84.5% | 100,393 | -71.1% | 0.00% | -84.6% |
| Q3 2017 | $504,000 | -53.4% | 347,659 | -13.2% | 0.01% | -56.7% |
| Q2 2017 | $1,081,000 | -47.5% | 400,614 | -21.2% | 0.03% | -49.2% |
| Q1 2017 | $2,060,000 | -30.8% | 508,649 | -28.3% | 0.06% | -33.7% |
| Q4 2016 | $2,977,000 | -56.3% | 708,969 | -29.3% | 0.09% | -62.3% |
| Q3 2016 | $6,818,000 | +20.4% | 1,002,677 | +2.4% | 0.24% | +36.4% |
| Q2 2016 | $5,661,000 | -14.0% | 979,554 | +3.9% | 0.17% | -15.6% |
| Q1 2016 | $6,581,000 | +1.3% | 942,804 | +4.5% | 0.20% | -1.4% |
| Q4 2015 | $6,496,000 | -2.6% | 902,286 | +16.6% | 0.21% | -6.7% |
| Q3 2015 | $6,671,000 | -46.6% | 773,970 | +0.1% | 0.22% | -42.5% |
| Q2 2015 | $12,486,000 | – | 773,071 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 324,148 | $1,874,000 | 2.19% |
| SABBY MANAGEMENT, LLC | 580,343 | $3,354,000 | 0.18% |
| WELCH & FORBES LLC | 979,554 | $5,661,000 | 0.17% |
| Hayek Kallen Investment Management | 12,015 | $69,000 | 0.05% |
| Indiana Trust & Investment Management CO | 13,250 | $77,000 | 0.04% |
| BOSTON FINANCIAL MANGEMENT LLC | 74,175 | $429,000 | 0.04% |
| HYMAN CHARLES D | 32,100 | $186,000 | 0.03% |
| Baker Brothers Advisors | 400,000 | $2,312,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 90,650 | $524,000 | 0.01% |
| Edge Wealth Management LLC | 3,000 | $17,000 | 0.01% |